drugset
drugset / Trial / NCT05514717

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717 ↗

Phase 1 Terminated 57 enrolled Day One Biopharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

Timeline

Start
2023-01-24
Primary completion
2026-05-22
Completion
2026-05-22

Outcome

Outcome not reported

Stopped: “Development discontinued.”

Drugs

EvaluationDrugModalityDoseRoute
Subject XMT-2056 Unknown — Intravenous

Indications

HER2 positive breast carcinoma non-small cell lung carcinoma